{"url_path":"/sec/pvla/8-k/2026-05-15/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1583648/0001193125-26-225317-index.html","accession_number":"0001193125-26-225317","cik":"0001583648","ticker":"PVLA","issuer_name":"PALVELLA THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1583648/0001193125-26-225317-index.html","primary_entity_key":"0001583648","primary_entity_name":"PALVELLA THERAPEUTICS, INC."},"word_count":74,"has_tables":true,"body_markdown":"## Item 8.01 Other Events.\n\nOn May 15, 2026, Palvella Therapeutics, Inc. (the “Company”) issued a press release announcing that new data from the Company’s Phase 2 TOIVA trial of QTORIN™ rapamycin in patients with cutaneous venous malformations were presented at the 83rd Annual Meeting of the Society for Investigative Dermatology. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference."}